Bush Signs Bill Providing FDA $1.73 Billion for Fiscal 2008
On December 26, 2007, President Bush signed into law H.R. 2764, which gives the FDA nearly $1.73 billion in funding for fiscal 2008.
On December 26, 2007, President Bush signed into law H.R. 2764, which gives the FDA nearly $1.73 billion in funding for fiscal 2008.
As reported by FDA News, the bill gives the FDA more than $79 million above the president’s budget request and $145 million above the fiscal 2007 funding level. The Center for Drug Evaluation and Research (CDER) will receive more than $682 million, with $41.9 million of that going to the Office of Generic Drugs. The Center for Biologics Evaluation and Research (CBER) will receive more than $236 million.
Details on the bill can be seen at thomas.loc.gov/cgi-bin/bdquery/z?d110:h.r.02764,
FDANews report
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
